Rituximab does not reset defective early B cell tolerance checkpoints

Type 1 diabetes (T1D) patients show abnormalities in early B cell tolerance checkpoints, resulting in the accumulation of large numbers of autoreactive B cells in their blood. Treatment with rituximab, an anti-CD20 mAb that depletes B cells, has been shown to preserve β cell function in T1D patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Invest
Main Authors: Chamberlain, Nicolas, Massad, Christopher, Oe, Tyler, Cantaert, Tineke, Herold, Kevan C., Meffre, Eric
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2015
Teme:
Brief Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701568/
https://ncbi.nlm.nih.gov/pubmed/26642366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI83840
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki